Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
- 26 January 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 150 (1), 96-102
- https://doi.org/10.1111/j.1365-2133.2004.05696.x
Abstract
Objective To validate the Eczema Area and Severity Index (EASI) by assessing its internal consistency, reliability and sensitivity to change and by correlating it to other efficacy parameters. Design Three short‐term and two long‐term double‐blind, randomized, controlled trials, performed in 138 study centres in Europe, South Africa, Australia, New Zealand, and North and South America. Patients and methods In total, 1550 paediatric patients with atopic dermatitis were studied. Pimecrolimus cream 1% was used twice daily to treat atopic dermatitis. The three short‐term studies were placebo controlled. The two long‐term studies evaluated the efficacy and safety of early intervention with pimecrolimus to prevent progression to disease flare requiring topical corticosteroid treatment, compared with reactive treatment with topical corticosteroids to treat flares of atopic dermatitis. Main outcome measures Five parameters were measured: (i) the EASI (range of score 0–72); (ii) Investigators' Global Assessment (IGA), using a six‐point (0–5) scale; (iii) patients' assessment, using a four‐point (0–3) scale; (iv) severity of pruritus assessment, using a four‐point (0–3) scale; and (v) a quality‐of‐life evaluation. Results The EASI score varied in parallel and in correlation with the IGA, pruritus and patients' assessment. All correlation coefficients were statistically different from 0 (P < 0·05). The EASI correlated well with each of its components, and all paired comparisons were within agreed limits. The EASI showed good sensitivity to changes in severity. Conclusion In a large, multinational patient population with atopic dermatitis, the EASI showed good validity, reliability and sensitivity to change and correlated well with other measures of severity. It therefore qualifies as a valid method of assessment in clinical studies of atopic dermatitis.Keywords
This publication has 12 references indexed in Scilit:
- Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infantsThe Journal of Pediatrics, 2003
- Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugJournal of Allergy and Clinical Immunology, 2002
- Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in ChildrenPublished by American Academy of Pediatrics (AAP) ,2002
- Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity scoreBritish Journal of Dermatology, 2002
- Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsJournal of the American Academy of Dermatology, 2002
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Measurement of disease activity and outcome in atopic dermatitisBritish Journal of Dermatology, 1996
- Severity Scoring of Atopic Dermatitis: The SCORAD IndexDermatology, 1993
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978